Previous Issue
Volume 6, March
 
 

J. Mol. Pathol., Volume 6, Issue 2 (June 2025) – 4 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
12 pages, 8458 KiB  
Case Report
Surgical Management of Intrathoracic Triton Tumors: Insights into Emerging Molecular and Epigenetic Mechanisms with a Case Series of Three Patients
by Alessandro Bonis, Alberto Busetto, Federica Pezzuto, Giulia Pagliarini, Vincenzo Verzeletti, Mario Pezzella, Giorgio Cannone, Eleonora Faccioli, Marco Mammana, Giovanni Maria Comacchio, Alessandro Rebusso, Marco Schiavon, Chiara Giraudo, Fiorella Calabrese, Andrea Dell’Amore, Samuele Nicotra, Angelo Paolo Dei Tos and Federico Rea
J. Mol. Pathol. 2025, 6(2), 10; https://doi.org/10.3390/jmp6020010 - 30 May 2025
Viewed by 161
Abstract
Malignant Triton Tumors (MTTs) are rare, high-grade malignant peripheral nerve sheath tumors (MPNSTs) frequently associated with Type 1 Neurofibromatosis (NF1). NF1, an autosomal dominant disorder, predisposes approximately 10% of affected individuals to developing MPNSTs, with 50% of these tumors occurring in NF1 patients, [...] Read more.
Malignant Triton Tumors (MTTs) are rare, high-grade malignant peripheral nerve sheath tumors (MPNSTs) frequently associated with Type 1 Neurofibromatosis (NF1). NF1, an autosomal dominant disorder, predisposes approximately 10% of affected individuals to developing MPNSTs, with 50% of these tumors occurring in NF1 patients, while others arise sporadically or in association with radiation exposure. MTTs predominantly affect anatomical regions rich in large nerves, such as the limbs, spinal root, and cranial nerves. Mediastinal presentations are exceedingly rare, posing significant diagnostic and therapeutic challenges. Current treatment strategies include surgical resection, chemotherapy, radiotherapy, and lung-sparing procedures for metastatic disease. Molecular studies of MPNSTs have revealed that NF1 mutations lead to dysregulation of the RAS signalling pathway, while epigenetic alterations (e.g., SUZ12/EED mutations) further contribute to tumor progression. Dysregulated phylogenetically conserved pathways, including Wnt/beta-catenin and non-canonical SHH signalling, play a role in sarcoma progression and Schwann cell transformation. Recent advances in miRNA research highlight their involvement in tumor invasion and progression, with dysregulated miRNA expression and chromatin remodeling contributing to the pathogenesis of these neoplasms. However, the distinct molecular profiles for MTTs remain incompletely understood. Further investigation of the genetic and epigenetic landscape is essential for improving our understanding and identifying potential therapies. Herein, we present a single-center retrospective case series of three patients with an intrathoracic triton tumor treated at our University Hospital between 2000 and 2024, serving as a starting point for future insights into MPNST pathobiology. Full article
Show Figures

Figure 1

14 pages, 631 KiB  
Article
Evaluation of Navify Mutation Profiler Tertiary Analysis Software Assessing for Hematologic Malignancies
by Ruby Singhrao, Michael J. Clark, Shikha Chugh, Lisha Capucion, Shuba Krishna, Ranga Yerram, Lili Niu, Adama Parham, Amy Harrell, John Duncan, Kristina Clark and Manana Javey
J. Mol. Pathol. 2025, 6(2), 9; https://doi.org/10.3390/jmp6020009 - 22 May 2025
Viewed by 307
Abstract
Background: Navify® Mutation Profiler (Navify MP) is a cloud-based, tertiary analysis software that provides curation, annotation, and reporting of somatic genomic alterations and biomarker signatures identified by next-generation sequencing. The Navify MP software leverages Association for Molecular Pathology/American Society of Clinical Oncology/College [...] Read more.
Background: Navify® Mutation Profiler (Navify MP) is a cloud-based, tertiary analysis software that provides curation, annotation, and reporting of somatic genomic alterations and biomarker signatures identified by next-generation sequencing. The Navify MP software leverages Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists (AMP/ASCO/CAP) Somatic Variant Classification Guidelines to provide information on detected somatic genomic variants and associated therapies according to region-specific approvals. Methods: This validation study assessed the accuracy of the Navify MP software and curation process for hematologic malignancies as compared to expert opinion. A total of 86 variants derived from hematologic malignancies (including myeloid and lymphoid leukemias, B cell lymphomas, and multiple myeloma) were used to contrive 12 VCF files. The VCFs were made up of the following classes of genomic alterations: single nucleotide variants, small insertions and deletions, fusions, and copy number alterations. Of the 86 variants, 42 were Tier IA, and 44 were non-Tier IA, based on AMP/ASCO/CAP classification. The study was performed at four sites with seven software users (molecular genetics experts). Results: Tier classification agreement between Navify MP and expert user assignment was 91.34% for Tier IA and 95.02% across all hematologic variants. The agreement on associated therapies for the Navify MP-classified Tier IA hematologic variants was 99.08%. Conclusions: Navify MP is a robust automated solution for genomic variant reporting of hematologic malignancies and remains up to date with evolving regional approvals and medical guidelines. Full article
Show Figures

Figure 1

9 pages, 1073 KiB  
Brief Report
Association of SEPT9 Gene Methylation with the Clinicopathologic Features and Fusobacterium nucleatum Infection in Colorectal Cancer Patients
by Siew-Wai Pang, Subasri Armon, Jack-Bee Chook, Kaik-Boo Peh, Suat-Cheng Peh and Sin-Yeang Teow
J. Mol. Pathol. 2025, 6(2), 8; https://doi.org/10.3390/jmp6020008 - 23 Apr 2025
Viewed by 344
Abstract
Background/Objectives: Colorectal cancer (CRC) is a significant global health issue. The identification of methylated Septin 9 (mSEPT9) as a biomarker for CRC represents a significant advancement in cancer diagnostics. On the other hand, Fusobacterium nucleatum (FN) is one of the [...] Read more.
Background/Objectives: Colorectal cancer (CRC) is a significant global health issue. The identification of methylated Septin 9 (mSEPT9) as a biomarker for CRC represents a significant advancement in cancer diagnostics. On the other hand, Fusobacterium nucleatum (FN) is one of the most studied cancer-related microbes in CRC. This study provided cohort evidence on the association of mSEPT9 with clinicopathologic characteristics and FN infection in CRC patients. Methods: Paired formalin-fixed paraffin-embedded (FFPE) tissue DNA (cancerous and adjacent non-cancer tissues) of eighty-three CRC patients was collected. Methylation-specific qPCR targeting the v2 promoter region of mSEPT9 was carried out on bisulfite-converted FFPE DNA. For FN detection, a TaqMan probe-based method targeting the 16S rRNA gene was used. The differences in mSEPT9 levels and FN expression between cancer and non-cancer tissues were evaluated. Association studies between mSEPT9 in the tumor and relative mSEPT9 levels with FN infection and available clinical data were conducted. Results: Higher mSEPT9 levels were found in the cancerous tissue compared to non-cancerous tissue (p < 0.0001). High mSEPT9 levels in the tumor were significantly associated with older patients (p < 0.001) and larger tumor size (p = 0.048) but not with other clinicopathologic variables. In double-positive patients where mSEPT9 was detected in both cancerous and non-cancerous tissue, the expression fold-change in mSEPT9, calculated using the 2−ΔΔCT formula, was significantly higher in patients with tumor size equal to or greater than 5 cm (p = 0.042). High levels of mSEPT9 in tumor were not associated with FN infection. However, high levels of FN infection were associated with mSEPT9 (p < 0.021). Conclusions: High levels of mSEPT9 are found in CRC tumor tissue and are associated with older age and larger tumor size, while high levels of FN infection are associated with mSEPT9 in this single-center cohort study. Full article
Show Figures

Figure 1

15 pages, 615 KiB  
Review
Current Topics on the Integration of Artificial Intelligence in the Histopathological and Molecular Diagnosis of Uveal Melanoma
by Serena Salzano, Giuseppe Broggi, Andrea Russo, Teresio Avitabile, Antonio Longo, Rosario Caltabiano and Manuel Mazzucchelli
J. Mol. Pathol. 2025, 6(2), 7; https://doi.org/10.3390/jmp6020007 - 17 Apr 2025
Viewed by 294
Abstract
Background: This review examines the expanding influence of artificial intelligence (AI) in the detection and management of uveal melanoma (UM). Methods: This work delves into the application of AI technologies such as machine learning (ML), deep learning (DL), and convolutional neural networks (CNNs) [...] Read more.
Background: This review examines the expanding influence of artificial intelligence (AI) in the detection and management of uveal melanoma (UM). Methods: This work delves into the application of AI technologies such as machine learning (ML), deep learning (DL), and convolutional neural networks (CNNs) in various diagnostic procedures, molecular profiling, and predictive analysis. Results: The discussion underscores AI’s potential to enhance diagnostic precision and efficiency. Particular focus is placed on its role in histopathological assessments of UM, where algorithms facilitate the analysis of whole-slide images (WSIs). AI contributes to more accurate tumor classification, assists in planning treatments, and improves the prediction of the prognostic indicators and molecular characteristics of the tumor. Conclusions: Despite these promising developments, this review acknowledges existing hurdles to AI implementation, including issues with data standardization and the interpretability of AI models. It emphasizes the need for further research to fully integrate AI into clinical workflows, ultimately aiming to improve patient care and outcomes. Full article
(This article belongs to the Special Issue Automation in the Pathology Laboratory)
Show Figures

Figure 1

Previous Issue
Back to TopTop